No registrations found.
ID
Source
Brief title
Health condition
Mood disturbances during OC use
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary objective is to evaluate the effect of DHEA on mood disturbances during OC use
Secondary outcome
- To assess general effects on well-being
- To assess satisfaction and health related quality of life
Background summary
Design:
A double-blind, placebo-controlled, randomised N=1 study
Subjects:
Main group: Six healthy OC users who complain of mood disturbances during OC use only
Subgroup (optional): Six healthy women who have had complaints of severe mood disturbances during OC use only and are willing to use OC for 6 subsequent cycles (= 28 days per cycle)
Study Medication:
All participants will receive two tablets of study medication, which will be ingested daily during the first 21 days of every cycle. These tablets will either contain DHEA or placebo. During the pill-free period (day 22 – 28), there is no intake of study medication.
Total treatment duration:
6 cycles of 28 days each with a randomised monthly regimen (3 cycles placebo and 3 cycles DHEA)
All participants will continue using their regular OC.
Clinical phase
Phase II
Primary objective:
To evaluate the effect of DHEA on mood disturbances during OC use
Secondary objectives:
· To assess the general effects on well-being
· To assess satisfaction and health related quality of life
Endpoints:
· Daily mood rating (1-5)
· General effect of study medication on subject’s well-being over the past 3 weeks
· Satisfaction and health related quality of life over the past week of OC intake
Study design
6 cycles of 28 days per subject
Intervention
All participants will receive two tablets of study medication, which will be ingested daily during the first 21 days of every cycle. These tablets will either contain DHEA or placebo. During the pill-free period (day 22 – 28), there is no intake of study medication. Total treatment duration: 6 cycles of 28 days each with a randomised monthly regimen (3 cycles placebo and 3 cycles DHEA). All participants will continue using their regular OC.
The effect of concomitant DHEA compared to placebo in OC users on mood disturbances will be measured with a daily mood rating. This is a daily rating on a 5-point scale (1 meaning very negative, and 5 meaning very positive) included in the Study Diary.
P.O. Box 4446
F.J.M.E. Roumen
Heerlen 6401 CX
The Netherlands
+31 (0)45 5766513
P.O. Box 4446
F.J.M.E. Roumen
Heerlen 6401 CX
The Netherlands
+31 (0)45 5766513
Inclusion criteria
1. Women using oral contraceptives for at least 3 months prior to screening and aged 20-35 years (inclusive) (for subgroup: Women, aged 20-40 years (inclusive), using a non-hormonal contraceptive method for at least 3 months and willing to use an OC for 6 subsequent cycles).
2. Report of mood disturbances, and attributing this to OC use as evidenced by in depth interview independently performed by two investigators.
3. Regular menstrual cycles (24-35 days) prior to last start of OC use.
4. Body mass index between (≥) 18 and (≤) 35 kg/m2.
5. Good physical and mental health as judged by the Investigator determined by medical and gynaecological history, physical examination, clinical laboratory and vital signs.
6. Willing to give informed consent in writing.
Exclusion criteria
1. Use of non-oral hormonal contraception in the 3 months prior to the screening (for subgroup: Use of oral hormonal contraception in the 3 months prior to the screening).
2. Intention to become pregnant during the study.
3. Lactation and/or pregnancy in the previous 6 months prior to screening.
4. Any clinically significant abnormality following review of medical and gynaecological history, clinical laboratory (haematology, biochemistry and androgen parameters) and physical examination and vital signs.
5. Contraindications for contraceptive steroids.
6. Use of one or more of the following medications:
- Psychoactive drugs
- Antihypertensive drugs
- Sex steroids other than the current OC
- Use at present or within 30 days before start study medication:
hydantoins, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, troglitazone, felbamate, rifampicin, rifabutin, griseofulvin, nelfinavir, ritonavir and St. John’s wort (Hypericum perforatum)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1400 |
| NTR-old | NTR1460 |
| Other | Protocol nummer van Pantarhei Bioscience : PR3082 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |